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ABSTRACT
Second-generation tyrosine kinase inhibitors (2G-TKIs) dasatinib and nilotinib 
produced historical rates of about 50% complete cytogenetic response (CCyR) and 
about 40% major molecular response (MMR) in chronic myeloid leukaemia (CML) 
patients failing imatinib. Direct comparisons between dasatinib and nilotinib are 
lacking, and few studies addressed the dynamics of deep molecular response (DMR) 
in a “real-life” setting.
We retrospectively analyzed 163 patients receiving dasatinib (n = 95) or nilotinib 
(n = 68) as second-line therapy after imatinib. The two cohorts were comparable 
for disease’s characteristics, although there was a higher rate of dasatinib use in 
imatinib-resistant and of nilotinib in intolerant patients.
Overall, 75% patients not in CCyR and 60% patients not in MMR at 2G-TKI start 
attained this response. DMR was achieved by 61 patients (37.4%), with estimated 
rate of stable DMR at 5 years of 24%. After a median follow-up of 48 months, 60% of 
patients persisted on their second-line treatment. Rates and kinetics of cytogenetic 
and molecular responses, progression-free and overall survival were similar for 
dasatinib and nilotinib. 
In a “real-life” setting, dasatinib and nilotinib resulted equally effective and 
safe after imatinib failure, determining high rates of CCyR and MMR, and a significant 
chance of stable DMR, a prerequisite for treatment discontinuation.
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INTRODUCTION
The introduction and worldwide diffusion of 
imatinib (IM) and, subsequently, second-generation 
tyrosine kinase inhibitors (2G-TKIs) has dramatically 
improved the prognosis of chronic myeloid leukaemia 
(CML) patients. Long-term follow-up of the IRIS study 
and the German CML-IV study reported estimated 
overall survival (OS) rates at 10 years with IM-based 
therapy around 82–83% [1, 2], close to that of the general 
population [3]. This excellent outcome is obtained despite 
that, in those two studies, 40 to 50% of patients interrupted 
IM therapy for unsatisfactory therapeutic efficacy or 
adverse events (AEs), outlining the efficacy of second-
line treatment. 
The first 2G-TKIs introduced in the clinical practice 
were dasatinib (DAS) and nilotinib (NIL), which had been 
initially tested in CML patients failing IM. When used in 
chronic phase (CP), both drugs result in around 50% of 
sustained complete cytogenetic response (CCyR) and 
40% of major molecular responses (MMR) [4, 5]. The two 
molecules have a favorable safety profile [6] and specific 
spectrum of activity against BCR-ABL1 kinase domain 
mutants [7]. 
However, due to the lack of direct comparative 
studies, it’s unclear whether any significant differences 
exist in terms of short and long-term activity among the 
two 2G-TKIs. Aim of our study was to describe efficacy 
of DAS and NIL in CP-CML patients after IM resistance 
or intolerance in a real-life setting. 
RESULTS
Patient characteristics
The present study included 163 CP-CML patients 
resistant or intolerant to IM that received either DAS (n 
= 95) or NIL (n = 68) as second-line therapy. Considering 
CML characteristic at diagnosis, the DAS and NIL cohorts 
were comparable for age, sex, BCR-ABL transcript type 
and risk scores (Sokal and EUTOS). Median duration of 
IM therapy was similar (DAS 19 months, range: 1–113; 
NIL 14 months, range: 1–149), but 27/95 patients (28%) 
received IM at doses >400 mg/day before DAS compared 
to only 9/68 (13%) before NIL (p = 0.03). There was a 
higher rate of switch to DAS than to NIL for secondary 
cytogenetic and/or molecular resistance (26/95, 27% vs 
7/68, 10%; p = 0.01) while more patients changed from 
IM to NIL due to intolerance (31/68, 46%, vs 21/95, 22% 
for DAS; p = 0.002). Rates of primary cytogenetic and/
or molecular resistance did not differ (47/95, 49% for 
DAS vs 28/68, 41% for NIL; p = 0.37), as other causes 
of switch (1/95, 1% for DAS vs 2/68, 3% for NIL; p = 
0.77). Hammersmith score was almost identical in the two 
groups. One patient in each cohort displayed a 2G-TKI-
sensitive ABL mutation at the time of IM failure, namely 
one M351T in a patient treated with DAS and one L364P 
in a patient treated with NIL (Table 1).
Cytogenetic and molecular responses after 
2G-TKIs
Complete cytogenetic response was attained in 
53/69 (77%) patients not in CCyR at the time of DAS 
start, compared to 27/37 (73%) patients not in CCyR at 
the time of NIL start (p = 0.81). Mean time to attain CCyR 
was similar (7.1 months for DAS and 5.3 months for NIL; 
p = 0.30). 
Major molecular response was achieved in 52/86 
(60%) patients not in MMR at the time of DAS start and in 
30/50 (60%) patients not in MMR at the time of NIL start 
(p = 1). Again, mean time to MMR was not different in 
the DAS and NIL cohorts (12.4 vs. 8.5 months; p = 0.14).
Deep molecular response was attained in 39 patients 
with DAS (41% of the total DAS population and 75% of 
those achieving MMR) and in 22 patients with NIL (32% 
of the total NIL cohort and 73% of those with MMR) (p 
= 1). 
Patients switched to 2G-TKIs for IM intolerance had 
better rates of response as compared to patients switched 
for IM resistance: CCyR 90% vs 72% (p = 0.09), MMR 
77% vs 56% (p = 0.07), DMR 59% vs 34% (p = 0.009) We 
compared cytogenetic and molecular responses obtained 
with DAS or NIL in IM-intolerant and IM-resistant 
patients separately, and we found no differences between 
the two 2G-TKIs (Figure 1).
Cytogenetic and molecular responses according 
to 2G-TKIs dose
DAS starting dose was 140 mg once-a-day (OD) in 
5 patients (5%), 100 mg OD in 79 patients (83%), and 
less than 100 mg OD in 11 patients (12%). NIL starting 
dose was 400 mg twice-a-day (BID) in 33 patients (49%), 
300 mg BID in 26 patients (38%), and 200 mg BID in 9 
patients (13%). Proportions of patients starting at different 
doses of each 2G-TKI were not different according to 
reason of IM failure (i.e. resistance or intolerance). Rates 
of cytogenetic and molecular responses were similar 
across different starting doses, both in DAS and in NIL 
cohorts (Table 2).
During follow-up, 2G-TKI dose was permanently 
reduced in 28/95 (29%) patients receiving DAS and 
21/68 (31%) patients receiving NIL. Median time from 
2G-TKI start to permanent dose reduction was 28.6 
months for DAS and 10.8 months for NIL (p = 0.055). 
The main causes of permanent dose reduction were non-
hematological toxicities (n = 30), recurrent hematological 
toxicities (n = 6), or pro-active reduction in patients with 
stable molecular responses and at risk for cardiovascular 
events (n = 8). Overall, 90% of patients maintained or 
improved over time the level of molecular response 
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attained at the time of permanent dose reduction, without 
differences between DAS and NIL cohorts.
Stable deep molecular response after 2G-TKIs
Stability of molecular response was assessable in 
154 patients (DAS = 89, NIL = 65) with serial Q-RT-
PCR analysis over a time-span of at least two years. The 
characteristics of this cohort are comparable with those 
of the entire population, with a median age of 55 years, 
a prevalence of male sex (60%), low-intermediate risk 
(82%), b2a2 BCR-ABL transcript (52%), a median IM 
duration of 19 months and resistance as main reason of 
switch to 2G-TKI (70%). 
Table 1: Patients’ characteristics at diagnosis and at start of 2G-TKI
DAS (n = 95) NIL (n = 68) P
Age median, years (range) 58 (18–88) 54 (20–80) 0.43
Sex, M/F ratio 56/39 44/24 0.56
BCR-ABL:  b2a2
                     b3a2
                     both
                     other/unknown
38 (40%)
35 (37%)
16 (17%)
6 (6%)
30 (44%)
19 (28%)
7 (10%)
12 (18%)
0.72
0.31
0.23
0.04
Sokal:          Low
                     Intermediate
                     High
                     Unknown
32 (34%)
42 (44%)
19 (20%)
2 (2%)
31 (46%)
27 (40%)
9 (13%)
1 (1%)
0.17
0.68
0.36
1.00
EUTOS:      Low
                    High
                    Unknown
81 (85%)
8 (9%)
6 (6%)
59 (87%)
4 (6%)
5 (7%)
0.97
0.76
1.00
IM therapy median, months (range) 19 (1-113) 14 (1-149) 0.18
IM dose escalation 27 (28%) 9 (13%) 0.03
Hammersmith score (low/evaluable) 57/83* (69%) 42/57* (74%) 0.65
Reason for 2G-TKI: Primary resistance
                    Secondary resistance
                    Intolerance
                    Other
47 (50%)
26 (27%)
21(22%)
1 (%)
28 (41%)
7(10%)
31 (46%)
2 (3%)
0.37
0.01
0.003
0.78
Figure 1: Rates of complete cytogenetic response (CCyR), major molecular response (MMR) and deep molecular 
response (DMR) in imatinib-resistant (IM-res) and -intolerant (IM-int) patients treated with second-line dasatinib 
(DAS) or nilotinib (NIL).
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Eighty-three patients (53.9%) never reached a 
DMR, 37 patients (24.0%) achieved an unstable DMR 
and 34 patients (22.1%) achieved a stable DMR. The 
cumulative incidence of stable DMR at 5 years was 
23.9% (95%CI: 15.3-31.7). (Figure 2A). Neither age, sex, 
risk, BCR-ABL transcript type, IM duration or 2G-TKI 
used correlated with the chance of attain a stable DMR; 
only the reason of switch to DAS or NIL was associated 
with such a response, as cumulative incidence of stable 
DMR at 5 years was 34% in intolerant patients and 19% 
in resistant patients (p = 0.058; Figure 2B). All but one 
patients subsequently attaining stable DMR had ≤10% 
BCR-ABL1 transcript level 3 months after 2G-TKIs start.
Long-term outcomes
With a median follow-up of 48 months (range 
1-147), 5-year TTF was similar for DAS (59.1%, 95%CI: 
47.9-68.7) and NIL (58.1%, 95%CI: 44.5-69.5; p = 0.62) 
(Figure 3A). Forty of 95 patients (34 42%) stopped DAS 
due to toxicity (22/40, 55%), resistance (13/40, 32%) or 
other causes (5/40, 12%). The commonest AEs leading 
to DAS permanent discontinuation were pleural effusion 
(n = 10), heart failure (n = 2) and arrhythmias (n = 2); 
we recorded one case of pulmonary arterial hypertension 
(PAH). Thirty-two patients received third-line therapy, 
namely NIL (n = 24), IM (n = 2), ponatinib (n = 2), 
bosutinib (n = 2) or other (hydroxyurea, n = 2). 
Twenty-six of 68 patients (38%) interrupted NIL 
for toxicity (14/26, 54%), resistance (9/26, 35%) or other 
causes (3/26, 11%). The most frequent toxicities causing 
permanent NIL stop were peripheral arterial obstructive 
disease (PAOD) (n = 4), cardiovascular events (n = 3), 
cutaneous adverse events (n = 2) and fluid retention (n = 
2). Nineteen patients were switched to alternative therapy 
with DAS (n = 13), ponatinib (n = 3), or bosutinib (n = 3). 
Five patients (4 in the NIL and 1 in the DAS 
group) received allogeneic stem cell transplantation for 
intolerance/resistance after their third-line TKI treatment 
(n = 4) or development of clonal abnormalities in the 
Philadelphia-negative cells (n = 1). 
In total, 6 patients (4 receiving DAS and 2 NIL) 
asked to stop therapy while in stable DMR: four of them 
are currently in treatment free remission after a median 
time of 25 months and two lost MMR and restarted 
therapy after 4 and 6 months, respectively.
We recorded 3 progressions to ABP in the DAS 
group and 1 in the NIL group. Sixteen patients in the DAS 
cohort died for CV events (n = 5), progression (n = 2), 
second neoplasms (n = 3), infection (n = 1) or physical 
deterioration/other causes (n = 5), compared to 9 deaths 
in the NIL cohort for CV event (n = 1), second neoplasms 
(n = 4), or physical deterioration/other causes (n = 4). 
Consequently, 5-year PFS was 85.5% (95% CI: 75.7–
91.5) for DAS and 87.6% (95% CI: 75.5–94.0) for NIL 
(p = 0.96) (Figure 3B) and 5-year OS was 87.9% (95% CI: 
78.6–93.3) for DAS and 89.1% (95% CI: 77.1–95.0) for 
NIL (p = 0.88) (Figure 3C). 
DISCUSSION
In this study, we analyzed the outcomes of second-
line 2G-TKI therapy in a “real life” setting of CML 
patients failing imatinib. We found higher rates of 
cytogenetic and molecular responses compared to those 
reported in the previous studies [4, 5], with a significant 
percentage of patients achieved a stable deep molecular 
response; more, we found that DAS and NIL are 
substantially equivalent and safe. 
In patients failing IM, selection of TKI is generally 
based on the safety profile and patient’s concomitant 
medical conditions, on the presence of BCR-ABL1 
Table 2: Cytogenetic and molecular responses according to 2G-TKI starting dose
DASATINIB (n = 95)
Starting dose 140 mg (n = 5) 100 mg (n = 79) <100 mg (n = 11) P
IM resistant/intolerant 4/1 65/14 6/5 0.12
CCyR 5/5 (100%) 41/55 (75%) 7/9 (78%) 0.58
MMR 4/5 (80%) 43/71 (60%) 5/10 (50%) 0.62
DMR 3/5 (60%) 31/75 (41%) 5/11 (45%) 0.83
Stable DMR 2/5 (40%) 19/79 (24%) 1/11 (9%) 0.35
NILOTINIB (n = 68)
Starting dose 800 mg (n = 33) 600 mg (n = 26) 400 mg (n = 9) P
IM resistant/intolerant 21/12 13/13 3/6 0.23
CCyR 17/21 (81%) 7/11 (64%) 3/5 (60%) 0.50
MMR 17/26 (65%) 8/17 (47%) 5/7 (71%) 0.44
DMR 12/30 (40%) 8/24 (33%) 2/7 (28%) 0.81
Stable DMR 6/33 (18%) 4/26 (15%) 2/9 (22%) 0.91
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mutations or on compliance to treatment [8, 9]. Second 
generation TKIs have never been compared head-to-
head in a prospective clinical trial, neither in the first- 
nor in the second-line setting, and a comparison of the 
results reported in the phase 2 studies that led to drugs’ 
registration are difficult because of different patient 
selection and protocol criteria [10]. A propensity score 
matching analysis in the front-line setting demonstrated 
that DAS and NIL offer similar response rates and survival 
outcomes [11]. Besides a few cost-effective analyses on 
second-line treatments after IM failure [12–14], the only 
experience focused on a comparison between DAS and 
NIL on clinical outcomes in IM-resistant or intolerant 
patients came from an online medical chart review of 
Figure 2: Cumulative incidence of stable deep molecular response in the whole population (A) and according to the reason of switch to 
2G-TKI (B).
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Figure 3: Time to treatment failure (A), progression-free survival (B) and overall survival (C) according to 2G-TKI treatment in CP-CML 
patients failing imatinib.
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597 CML patients treated by 122 haematologists and 
oncologists in the United States [15]. Although NIL was 
found to be associated with a longer PFS (p = 0.03) and 
a trend toward a better OS (p = 0.067), these results may 
have been biased by various factors, such as the low 
mean number of patients per physician (less than 5) and a 
median follow-up of less than 12 months. 
With the limits of all retrospective and non-
randomized studies, our analysis was carried on in 10 
haematological centers from North-Eastern Italy, with 
experience in CML management, including all consecutive 
cases fitting inclusion criteria to minimize selection bias. 
Our data suggest a similar efficacy of DAS and NIL 
after IM failure in CP-CML, with high rates of responses and 
excellent long-term survival. Interestingly, due to the earlier 
DAS availability In Italy, approximately two years before 
NIL, in the years 2007-08 we switched to DAS 24 patients 
compared to only 2 treated with NIL. So, it is arguable that 
a group of IM-resistant patients, that are known to respond 
less to 2G-TKIs than the intolerant ones [16], received the 
first available 2G-TKI, thus unbalancing the two cohorts; 
nonetheless, the long-term survival of DAS- and NIL-treated 
patients was almost identical and close to 90%.
Compared to the published data from clinical 
trials [4, 5], in our real-life experience the rates of CCyR 
and MMR were higher, around 70% vs 50% and 65% 
vs 40%, respectively. This may be due to both a longer 
experience with 2G-TKIs and lack of protocol constraints, 
enabling a steadier use of the drugs, as confirmed by a 
significant proportion of patients remaining in DAS and 
NIL treatment over time. Notably, after non-severe or 
recurrent toxicities, the 2G-TKI dose was permanently 
reduced in about one third of our patients, and 90% of 
them maintained or improved their molecular response 
after dose reduction, demonstrating the advantage of 
dose adaptation in clinical practice over the adherence 
to strict protocol rules. As a consequence, after a median 
observation time of four years, more than 50% of our 
patients were still in treatment with their second-line 
TKI, a figure almost double than those reported by Shah 
et al. for DAS [4] and Giles et al. for NIL [5]. Very few 
patients experienced the potentially life-threatening AEs 
described for both DAS and NIL [17, 18], as we recorded 
only one case of PAH under DAS and two cases of PAOD 
with NIL. More generally, safety profile of both drugs 
was acceptable, with 15–20% discontinuing therapy due 
to drug-related adverse events, figures in line with those 
previously reported for DAS [19] and NIL [5]. 
Long-term use of 2G-TKI in second-line treatment 
after IM failure resulted in about 40% of patients achieving 
the “safe haven” of DMR, with around 60% of them 
in stable MR4, a strong prerequisite for discontinuing 
treatment [20]. A recent work focused on the use of DAS 
or NIL as third-line treatment after failure of 2 previous 
TKIs showed that 16 out of 21 patients in this setting 
were able to gain and/or maintain an optimal molecular 
response and 4 of them stopped the treatment [21]. 
Though the number of patients who actually attempted 
discontinuation in our cohort is very small, these data 
suggest that the goal of treatment-free remission could be 
pursued also in patients receiving 2G-TKI after IM failure. 
To date, there are no clear indications to guide 
treatment of CP-CML patients failing IM [22]. The most 
widely used tools are BCR-ABL1 mutational status and 
patient’s comorbidities. At present, however, only a small 
and definitive number of mutations have been shown to 
confer insensitivity to DAS (V299L and F317L/V/I/C), 
NIL (Y253H, E255K/V, and F359I/V/C) or both (T351I)
[23], while the percentage of patients for whom a specific 
concomitant disease may preclude the use of one of the two 
2G-TKIs does not exceed 20% [24]. Our study indicates 
that, in a “real life” setting, both DAS and NIL are equally 
effective, with high rates of cytogenetic and molecular 
responses, good persistence on therapy with acceptable 
toxicity and a significant chance to achieve a stable DMR. 
MATERIALS AND METHODS
We retrospectively analysed a database of 
consecutive CML patients treated at 10 Italian 
haematologic centres between January 2007 and 
December 2015. The inclusion criteria were as follows: 
(1) age ≥18 years; (2) diagnosis of CP CML; (3) use 
of DAS or NIL as second-line therapy after resistance 
or intolerance to IM; (4) no evolution to accelerated or 
blast phase (ABP) at the time of DAS or NIL start; (5) 
no detection of BCR-ABL1 mutations known to confer 
resistance to DAS (V299L and F317L/V/I/C), NIL 
(Y253H, E255K/V and F359V/I/C) or both (T315I). All 
patients who met the required criteria were included in 
the analysis. We compared the characteristics of the two 
groups at the time of CML diagnosis and at the time of IM 
failure, including the cause of switch to 2G-TKI, duration 
of IM therapy, IM dose escalation and Hammersmith 
score to predict the probability of response to 2G-TKIs 
[25]. Starting dose of 2G-TKI, causes of prolonged (i.e. 
lasting ≥1 month) or permanent interruption, and causes of 
permanent dose reduction were recorded for each patient, 
along with the dynamics of molecular response upon dose 
modifications. Cytogenetic and molecular responses were 
evaluated according to the 2013 ELN recommendations 
[26]. Major molecular response (MMR) was defined 
as BCR-ABLIS ratio <0.1%. Deep molecular response 
(DMR4) was defined as BCR-ABLIS ratio ≤0.01% or 
undetectable disease with ≥10,000 ABL copies, i.e. MR4. 
Patients in MR4 lasting ≥2 years with at least a Q-RT-PCR 
test every 6 months and ongoing at the last follow-up were 
defined as in stable DMR.
Time to treatment failure (TTF) was calculated 
from the start of 2G-TKI to the earliest date of any of 
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the following events: progression to ABP, death for any 
cause at any time, treatment discontinuation for primary 
or secondary resistance or intolerance. Progression free 
survival (PFS) was defined as the time from the start 
of 2G-TKI to ABP or death. Overall survival (OS) was 
defined as the time from the start of 2G-TKI to the date of 
death from any cause. 
Statistical analysis
The baseline characteristics of patients and rates 
of AEs were compared between the groups of NIL- and 
DAS-treated patients using the Pearson chi-square or 
Fisher exact test for categorical variables and Mann–
Whitney U test for continuous variables. TTF, PFS, and 
OS were calculated using the Kaplan–Meier method, and 
the values were compared using the long-rank test. All 
tests were two-sided, and a p value < 0.05 was considered 
statistically significant. All statistical analyses were 
performed using the EZR package [27]. 
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